 | | CV risicomanagement: First things first |
|  | | CV risicomanagement : First things First |
|
 | | 70th Scientific Sessions ADA |
|  | | DM 2, HbA1c, en CHZ |
|
 | | Haffner, NEJM,1998 |
|  | | DCCT mean HbA1c in type 1 diabetes |
|
 | | EDIC study follow-up 8 years after DCCT |
|  | | DCCT / EDIC study cardiovascular disease |
|
 | | UKPDS : relatie HbA1c en complicaties |
|  | | Post-Trial Changes in HbA1c |
|
 | | Myocardial Infarction Hazard Ratio |
|  | | Myocardial Infarction Hazard Ratio |
|
 | | ADVANCE : HbA1c : 6,4 vs 7,0 % |
|  | | ACCORD : HbA1c : 6,4 vs 7,5 % |
|
 | | Scherpe regulatie bij dm2 : |
|  | | Post-Trials Changes in Blood Pressure |
|
 | | Myocardial Infarction Hazard Ratios |
|  | | BP : hoe laag ? : ACCORD-BP studie |
|
 | | BP : hoe laag ? : ACCORD-BP studie |
|  | | Lipiden-verlaging bij dm2 : statines |
|
 | | Lipiden-verlaging bij dm2: fibraten |
|  | | Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD (Detection of silent Ischemia in Asymptomatic Diabetic subjects) |
|
 | | Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD (Detection of silent Ischemia in Asymptomatic Diabetic subjects) |
|  | | Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD |
|
 | | Screening for Cardiovascular disease in asymptomatic Diabetics : Lessons from DIAD:1-3 |
|  | | Cardiovasulaire Incidenten en glucose-verlagende medicatie : effect van metformin : de REACH-studie |
|
 | | REACH-registry |
|  | | REACH-registry |
|
 | | REACH-registry |
|  | | REACH-registry |
|
 | | REACH-registry |
|  | | Cardiovasulaire Incidenten en glucose-verlagende medicatie “ The Rosiglitazone-story ” |
|
 | | “ the rosiglitazone-story “ |
|  | | “ the rosiglitazone-story “ |
|
 | | “ the rosiglitazone-story “ |
|  | | “ the rosiglitazone-story “ |
|
 | | Cardiovasculaire effecten van glucoseverlagende medicatie : GLP-1-analogen |
|  | | Slide 38 |
|
 | | Slide 39 |
|  | | Subgroep : TG > 2,3 en HDL-c < 0,9 |
|
 | | Subgroep : TG > 2,3 en HDL-c < 0,9 |
|  | | Voor de praktijk : Diabetes 2 en Cardiovasculaire complicaties |
|
 | | Voor de praktijk : Diabetes 2 en Cardiovasculaire complicaties |
|
Deel deze pagina met collega's en vrienden: